MARKET

GRFS

GRFS

Grifols S A
NASDAQ
7.58
-0.12
-1.50%
Opening 14:42 03/24 EDT
OPEN
7.59
PREV CLOSE
7.69
HIGH
7.71
LOW
7.57
VOLUME
475.40K
TURNOVER
--
52 WEEK HIGH
10.96
52 WEEK LOW
6.09
MARKET CAP
5.21B
P/E (TTM)
10.93
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GRFS last week (0316-0320)?
Weekly Report · 1d ago
Grifols shares results of Chronos Platforms identifying early Parkinson’s
TipRanks · 03/17 12:43
Grifols' Chronos-PD Study Demonstrates That Biological Changes In Individuals With Parkinson's Disease Occur More Than A Decade Before Clinical Diagnosis, With Potential Future Implications For Early Detection And Intervention
Benzinga · 03/17 12:30
Grifols Chronos-PD study links Parkinson’s molecular changes to up to 12 years before diagnosis
Reuters · 03/17 12:28
Grifols to present Chronos-PD data in 13 AD/PD conference sessions
Reuters · 03/17 11:19
Weekly Report: what happened at GRFS last week (0309-0313)?
Weekly Report · 03/16 10:30
Grifols secures commitments for a new USD 2 billion revolving credit facility
Reuters · 03/16 07:21
Grifols expands AMBAR Alzheimer’s plasma exchange program with new clinics in Madrid, Mallorca and Alicante
Reuters · 03/12 09:41
More
About GRFS
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

Webull offers Grifols SA - ADR stock information, including NASDAQ: GRFS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GRFS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GRFS stock methods without spending real money on the virtual paper trading platform.